Open AccessImplementation and Operational Research
Author(s) -
Tyler Smith,
Taraz Samandari,
Taiwo Abimbola,
Barbara J. Marston,
Nalinee Sangrujee
Publication year - 2015
Publication title -
journal of acquired immune deficiency syndromes
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.162
H-Index - 157
eISSN - 1944-7884
pISSN - 1525-4135
DOI - 10.1097/qai.0000000000000783
Subject(s) - medicine , tuberculin , isoniazid , tuberculosis , antiretroviral therapy , human immunodeficiency virus (hiv) , cost effectiveness , immunology , viral load , pathology , risk analysis (engineering)
In Botswana, a 36-month course of isoniazid treatment of latent tuberculosis (TB) infection [isoniazid preventive therapy (IPT)] was superior to 6-month IPT in reducing TB and death in persons living with HIV (PLHIV), having positive tuberculin skin tests (TSTs) but not in those with negative TST. We examined the cost-effectiveness of IPT in Botswana, where antiretroviral therapy (ART) is widely available.